Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) EBITDA (2016 - 2026)

Heron Therapeutics filings provide 15 years of EBITDA readings, the most recent being -$8.1 million for Q1 2026.

  • On a quarterly basis, EBITDA fell 409.61% to -$8.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$30.9 million, a 297.89% decrease, with the full-year FY2025 number at -$20.2 million, down 48.78% from a year prior.
  • EBITDA hit -$8.1 million in Q1 2026 for Heron Therapeutics, down from -$2.9 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $3.6 million in Q4 2024 to a low of -$63.9 million in Q1 2022.
  • Median EBITDA over the past 5 years was -$10.7 million (2023), compared with a mean of -$19.7 million.
  • Biggest five-year swings in EBITDA: skyrocketed 182.51% in 2025 and later tumbled 409.61% in 2026.
  • Heron Therapeutics' EBITDA stood at -$19.8 million in 2022, then soared by 45.99% to -$10.7 million in 2023, then soared by 133.95% to $3.6 million in 2024, then crashed by 181.13% to -$2.9 million in 2025, then crashed by 175.29% to -$8.1 million in 2026.
  • The last three reported values for EBITDA were -$8.1 million (Q1 2026), -$2.9 million (Q4 2025), and -$17.5 million (Q3 2025) per Business Quant data.